Related references
Note: Only part of the references are listed.Statin Use and Musculoskeletal Pain Among Adults With and Without Arthritis
Catherine Buettner et al.
AMERICAN JOURNAL OF MEDICINE (2012)
Rare versus common variants in pharmacogenetics: SLCO1B1 variation and methotrexate disposition
Laura B. Ramsey et al.
GENOME RESEARCH (2012)
CPIC: Clinical Pharmacogenetics Implementation Consortium of the Pharmacogenomics Research Network
M. V. Relling et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2011)
Statin-induced myopathy: a review and update
Thura T. Abd et al.
EXPERT OPINION ON DRUG SAFETY (2011)
Genetics and Variable Drug Response
Russell A. Wilke et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2011)
Effects on 11-year mortality and morbidity of lowering LDL cholesterol with simvastatin for about 5 years in 20 536 high-risk individuals: a randomised controlled trial
R. Bulbulia et al.
LANCET (2011)
Organic Anion Transporting Polypeptide 1B1: a Genetically Polymorphic Transporter of Major Importance for Hepatic Drug Uptake
Mikko Niemi et al.
PHARMACOLOGICAL REVIEWS (2011)
Genetic involvement in statins induced myopathy. Preliminary data from an observational case-control study
Luca Puccetti et al.
ATHEROSCLEROSIS (2010)
Transporter Pharmacogenetics and Statin Toxicity
M. Niemi
CLINICAL PHARMACOLOGY & THERAPEUTICS (2010)
Individualising the risks of statins in men and women in England and Wales: population-based cohort study
Julia Hippisley-Cox et al.
HEART (2010)
STATIN-ASSOCIATED MYOPATHY AND ITS EXACERBATION WITH EXERCISE
Benjamin M. Meador et al.
MUSCLE & NERVE (2010)
Pitavastatin approved for treatment of primary hypercholesterolemia and combined dyslipidemia
Jun Sasaki
VASCULAR HEALTH AND RISK MANAGEMENT (2010)
Impact of OATP transporters on pharmacokinetics
A. Kalliokoski et al.
BRITISH JOURNAL OF PHARMACOLOGY (2009)
The SLCO1B1*5 Genetic Variant Is Associated With Statin-Induced Side Effects
Deepak Voora et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2009)
Rhabdomyolysis reports show interaction between simvastatin and CYP3A4 inhibitors
Christopher Rowan et al.
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY (2009)
SLCO1B1Variants and Statin-Induced Myopathy — A Genomewide Study
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Different effects of SLCO1B1 polymorphism on the pharmacokinetics of atorvastatin and rosuvastatin
M. K. Pasanen et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2007)
Identifying genetic risk factors for serious adverse drug reactions: current progress and challenges
Russell A. Wilke et al.
NATURE REVIEWS DRUG DISCOVERY (2007)
Statin and statin-fibrate use was significantly associated with increased myositis risk in a managed care population
David L. McClure et al.
JOURNAL OF CLINICAL EPIDEMIOLOGY (2007)
Risk factors for statin-associated rhabdomyolysis
Stephanie Schech et al.
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY (2007)
SLCO1B1 polymorphism markedly affects the pharmacokinetics of simvastatin acid
Marja K. Pasanen et al.
PHARMACOGENETICS AND GENOMICS (2006)
Drug and bile acid transporters in rosuvastatin hepatic uptake: Function, expression, and pharmacogenetics
Richard H. Ho et al.
GASTROENTEROLOGY (2006)
Final conclusions and recommendations of the National Lipid Association Statin Safety Assessment Task Force
JM McKenney et al.
AMERICAN JOURNAL OF CARDIOLOGY (2006)
Risk factors for rhabdomyolysis with simvastatin and atorvastatin
Kathlyn J. Ronaldson et al.
DRUG SAFETY (2006)
Combinatorial pharmacogenetics
RA Wilke et al.
NATURE REVIEWS DRUG DISCOVERY (2005)
Effect of OATPIBI (SLCOIBI) variant alleles on the pharmacokinetics of pitavastatin in healthy volunteers
JY Chung et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2005)
Functional characterization of SLCO1B1 (OATP-C) variants, SLCO1B1*5, SLCO1B1*15 and SLCO1B1*15+C1007G, by using transient expression systems of HeLa and HEK293 cells
Y Kameyama et al.
PHARMACOGENETICS AND GENOMICS (2005)
Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes - Phase Z of the A to Z trial
JA de Lemos et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2004)
High plasma pravastatin concentrations are associated with single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide-C (OATP-C, SLCO1B1)
M Niemi et al.
PHARMACOGENETICS (2004)
Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs
DJ Graham et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2004)
The effect of gemfibrozil on the pharmacokinetics of rosuvastatin
DW Schneck et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2004)
Lovastatin and beyond: The history of the HMG-CoA reductase inhibitors
JA Tobert
NATURE REVIEWS DRUG DISCOVERY (2003)
Statin-associated myopathy
PD Thompson et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2003)
Gemfibrozil greatly increases plasma concentrations of cerivastatin
JT Backman et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2002)
MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomised placebo-controlled trial
R Collins et al.
LANCET (2002)
Polymorphisms in OATP-C -: Identification of multiple allelic variants associated with altered transport activity among European- and African-Americans
RG Tirona et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2001)
Plasma concentrations of active simvastatin acid are increased by gemfibrozil
JT Backman et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2000)
Share Paper
